Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2006

View Archived Issues

COL-3 shows promise in AIDS-related Kaposi's sarcoma

Matuzumab/gemcitabine combination feasible in pancreatic cancer

Elemene inhibits laryngeal cancer cell growth

Activity of BXL-628 indicative of efficacy in overactive bladder

DDP-225 improves bladder irritation and capacity in animal models

IP-751 demonstrates efficacy against bladder irritation in vivo

Vertex begins clinical trial for potential cystic fibrosis treatment

Arginox continues to enroll TRIUMPH trial for cardiogenic shock

R-343 selected for advanced preclinical development as allergic asthma treatment

Neotropix's oncolytic virus candidate SVV-001 cleared for clinical trials

Biosite voluntarily withdraws PMA for Triage Stroke Panel

Amarin acquires rights to novel formulation of apomorphine

Agreement for preclinical testing of synDNA H5N1 avian flu vaccine candidates

Terumo and Yakult Honsha to codevelopment liposomal irinotecan

deCODE advances DG-031 to phase III for heart attack prevention

New spinout Cabrellis Pharmaceuticals begins operations

Collaboration to develop treatment for spinal muscular atrophy

Midway receives funding for gastrointestinal therapy development program

Peptech acquisition strengthens company's product pipeline

Health Canada approves Aromasin for adjuvant sequential therapy in early-stage breast cancer

Orion and Abbott consider continued development of levosimendan

Bristol-Myers Squibb discontinues muraglitazar development

Promising phase II results reported for leuprolide in Alzheimer's disease treatment

Therapeutic agents for respiratory disorders described in recent patents

Recent patents disclose new therapeutics for psychological disorders

Remicade approved as first biologic treatment for active pediatric Crohn's disease

Agents for arthritis and other inflammatory disorders reported

Prostaglandin D2 receptor 1 antagonist effective in reducing nicotinic acid-induced vasodilation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...